Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX in Metastatic Breast Cancer
NCT00216021Phase 2Completed
- Sponsor
- Hoosier Cancer Research Network
- Start
- Mar 2004
- Primary completion
- Jun 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in breast cancer, sponsored by Hoosier Cancer Research Network. Primary endpoint: Objective Response Rate at 36 months. Started Mar 2004; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00216021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216021.